🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2024-520353-21-00
Authorised Phase I

A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms.

2024-520353-21-00 · tracked via the Priya Life Science EU tracker
Sponsor
Incyte Corp.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
14/01/2026
Enrollment target
120
Sites
Norway, Germany, France, Italy

Condition studied

Myeloproliferative Neoplasms

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-520353-21-00 on CTIS ↗ ← All trials in the EU